Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

NCT00502242
View directory record Official record
Conditions
Kidney Transplant
Interventions
ramipril
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
24
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Oct 28, 2026, 3:09 PM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

NCT03858075
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BLU-782, Placebo, BLU-782 taken with food
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
19 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

NCT07601074
View directory record Official record
Conditions
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions
Lopinavir / ritonavir
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
22 Years to 50 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

NCT02188459
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Bupropion
Drug
Lead sponsor
Henry Kranzler
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

NCT04849559
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 2 Interventional

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

NCT07209462
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
13 Years to 45 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Irvine, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 3:09 PM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 3 Interventional

Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

NCT00603577
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Xaliproden
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 28, 2026, 3:09 PM EDT
Not listed Phase 2 Interventional

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

NCT04822961
View directory record Official record
Conditions
mCRPC
Interventions
Placebo, Senaparib
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy

NCT00891683
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Chronic Pain
Interventions
AEG33773 oral dosing
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Santa Monica, California • Cincinnatti, Ohio • Kettering, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2010 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01309945
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Placebo matching with BMS-820836, BMS-820836, Placebo matching with Duloxetine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arkansas • Arcadia, California • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 28, 2026, 3:09 PM EDT
Terminated Phase 2 Interventional Results available

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

NCT03473340
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions
Pirfenidone Capsule, Placebo Capsule
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Not applicable Interventional Results available

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04724291
View directory record Official record
Conditions
Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions
MAGNET
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

NCT01479478
View directory record Official record
Conditions
Infection, Pregnancy
Interventions
Placebo, Probiotic dietary supplement
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Aptos, California • Santa Cruz, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 28, 2026, 3:09 PM EDT
Completed Phase 2 Interventional Results available

A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana

NCT01005810
View directory record Official record
Conditions
Cannabis Dependence
Interventions
N-Acetylcysteine, placebo, Contingency Management
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 21 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 28, 2026, 3:09 PM EDT